Famar Expands European Footprint with Acquisition of German Sterile Manufacturing Facility

Greek contract development and manufacturing organization (CDMO) Famar is set to acquire a sterile manufacturing facility in Homburg, Germany, from MiP Pharma. This strategic move is part of Famar's plan to expand its European operations and enhance its production capabilities for high-value dosage forms.

Acquisition Details and Strategic Implications

The acquisition, announced on May 13, 2025, will add aseptic and lyophilized fill-finish capacity to Famar's portfolio. Upon completion of the deal, Famar's European production footprint will expand to seven facilities, including four in Greece and one each in Spain and Italy.

Konstantinos Rengis, Famar's Chief Executive, emphasized the strategic importance of the acquisition, stating, "There is scarcity in high-quality sterile infrastructure in Europe and the investment will provide us immediate capacity for our growing business. The Homburg facility offers us the opportunity to expand our business with international clients."

Famar's Recent Growth and Market Position

This latest expansion comes less than a year after MidEuropa, a private equity firm, acquired a majority stake in Famar from ECM Partners and Metric Capital Partners in July 2024. At the time of that acquisition, Famar employed approximately 1,900 people.

The company's current growth trajectory marks a significant turnaround from its position prior to the COVID-19 pandemic. In October 2019, Famar was facing financial difficulties and sold half of its then network of 11 sites to French CDMO Delpharma in a deal worth over $250 million. That sale included facilities in France, the Netherlands, and Canada.

Industry Implications and Future Outlook

The acquisition of the Homburg facility underscores the increasing demand for high-quality sterile manufacturing capabilities in Europe. As pharmaceutical companies continue to outsource production, CDMOs like Famar are positioning themselves to meet this growing need.

While financial details of the purchase were not disclosed, the move is expected to strengthen Famar's competitive position in the European CDMO market. The addition of sterile manufacturing capabilities, particularly in aseptic and lyophilized fill-finish, aligns with industry trends towards more complex and specialized pharmaceutical production.